PRQR vs. SCPH, GOSS, AEON, GLSI, TELO, ACET, IVA, SKYE, CAPR, and CRVO
Should you be buying ProQR Therapeutics stock or one of its competitors? The main competitors of ProQR Therapeutics include scPharmaceuticals (SCPH), Gossamer Bio (GOSS), AEON Biopharma (AEON), Greenwich LifeSciences (GLSI), Telomir Pharmaceuticals (TELO), Adicet Bio (ACET), Inventiva (IVA), Skye Bioscience (SKYE), Capricor Therapeutics (CAPR), and CervoMed (CRVO). These companies are all part of the "pharmaceutical preparations" industry.
scPharmaceuticals (NASDAQ:SCPH) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their community ranking, media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.
ProQR Therapeutics received 168 more outperform votes than scPharmaceuticals when rated by MarketBeat users. However, 66.10% of users gave scPharmaceuticals an outperform vote while only 61.95% of users gave ProQR Therapeutics an outperform vote.
In the previous week, ProQR Therapeutics had 7 more articles in the media than scPharmaceuticals. MarketBeat recorded 11 mentions for ProQR Therapeutics and 4 mentions for scPharmaceuticals. ProQR Therapeutics' average media sentiment score of 0.59 beat scPharmaceuticals' score of 0.36 indicating that scPharmaceuticals is being referred to more favorably in the media.
scPharmaceuticals has a beta of 0.06, meaning that its stock price is 94% less volatile than the S&P 500. Comparatively, ProQR Therapeutics has a beta of 0.21, meaning that its stock price is 79% less volatile than the S&P 500.
ProQR Therapeutics has lower revenue, but higher earnings than scPharmaceuticals. ProQR Therapeutics is trading at a lower price-to-earnings ratio than scPharmaceuticals, indicating that it is currently the more affordable of the two stocks.
scPharmaceuticals presently has a consensus target price of $19.33, suggesting a potential upside of 329.63%. ProQR Therapeutics has a consensus target price of $3.60, suggesting a potential upside of 79.10%. Given ProQR Therapeutics' higher possible upside, equities research analysts clearly believe scPharmaceuticals is more favorable than ProQR Therapeutics.
scPharmaceuticals has a net margin of -403.22% compared to scPharmaceuticals' net margin of -431.65%. scPharmaceuticals' return on equity of -56.71% beat ProQR Therapeutics' return on equity.
89.5% of scPharmaceuticals shares are held by institutional investors. Comparatively, 32.7% of ProQR Therapeutics shares are held by institutional investors. 4.7% of scPharmaceuticals shares are held by company insiders. Comparatively, 8.4% of ProQR Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
ProQR Therapeutics beats scPharmaceuticals on 10 of the 17 factors compared between the two stocks.
Get ProQR Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRQR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PRQR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ProQR Therapeutics Competitors List
Related Companies and Tools
